ABT Abbott Laboratories
USHealthcareAs of 2026-10-08 09:52
Why ABT matters now
Abbott Laboratories (ABT) is a US stock in Healthcare. The latest InvestLog snapshot shows $98.92 with +0.19% on the session and $171.17B in market capitalization; recent performance reads 1-month -0.50% and YTD -29.46%.
The latest financial table shown here is Q1 2026, with revenue of $11.16B, net income of $1.08B, and EPS of $0.62. Investors can compare that operating picture with valuation signals such as P/E 26.72 and FCF yield 4.8%.
InvestLog's latest related AI research is a Rating Change note titled "Barclays initiates coverage of ABT with Overweight". The latest indexable market news headline is "Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $125.00; recent insider activity includes Stratton John G filing P-Purchase; recent congressional disclosure data includes Julie Johnson Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
26.72
PEG
—
P/B
2.97
P/S
3.41
EV/EBITDA
16.16
DCF Value
$150.77
FCF Yield
4.8%
Div Yield
2.8%
Margins & Returns
Gross Margin
56.4%
Operating Margin
18.2%
Net Margin
13.9%
ROE
12.2%
ROA
5.7%
ROIC
6.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $11.16B | $1.08B | $0.62 |
| Q4 2025 | $11.46B | $1.78B | $1.02 |
| FY 2025 | $44.33B | $6.52B | $3.72 |
| Q3 2025 | $11.37B | $1.64B | $0.94 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$127.46
Target (Median)
$125.00
Target Range
$92.00 - $152.00
Trading Activity
Insider Trades
Congress Trades
Related AI Research
Barclays initiates coverage of ABT with OverweightBarclays 首次覆盖 雅培 (ABT),初始评级 增持(Overweight)
On 2026-10-06, Barclays initiated coverage of ABT with a Overweight rating.Barclays 于 2026-10-06 首次覆盖 ABT,初始评级为 增持(Overweight)。
ABT receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart conditionAbbott Laboratories(ABT)的 new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition 获美国 FDA 批准
ABT receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition.Abbott Laboratories(ABT)的 new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition 获美国 FDA 批准。
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
0.62
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.